Aclaris falls after mid-stage trial setback for dermatitis drug

Aclaris Therapeutics

10/01/2024 15:47

(Updates)
    ** Shares of drug developer Aclaris Therapeutics  ACRS.O 
fall ~23.8% to 97 cents 
        ** Stock top loser on Nasdaq biotechnology index  .NBI  
  
    ** Co says the once-daily version of its atopic dermatitis
drug did not show statistical significance in a mid-stage trial
    ** Adds, the twice daily version met the trial's main goal
    ** Atopic dermatitis causes itching, leading to skin
reddening, swelling and cracking 
    ** Stock fell 93.3% in 2023
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))